SHS Gesellschaft für Beteiligungsmanagement mbH

Newsletter

1. August 2023 - Newsletter

This year the annual SHS Investors Day and the shareholders’ meetings of the SHS funds were held again in Tübingen

Our investors, portfolio representatives, SHS senior advisors and healthcare experts were invited to the Hotel Krone in the centre of Tübingen. The day offered exciting presentations on healthcare investments and outlooks on economic developments and medical innovations in the coming years. Furthermore, four of the SHS portfolio companies gave exciting presentations about their companies and […]

Read more
1. August 2023 - Newsletter, Portfolio News

SHS offers its portfolio companies a regular workshop for mutual exchange and training purposes

Another format that SHS has specifically created for its portfolio companies is the SHS portfolio workshops. These take place quarterly, covering various topics. The aim is to discuss topics that concern a large proportion of the portfolio companies and to provide the companies the opportunity to exchange ideas and knowledge, to discuss approaches to solving […]

Read more
1. August 2023 - Newsletter

SHS Capital has launched a new training format – the SHS Academy – for its newer employees as well as current and former interns

The new training and networking format is created for newer employees as well as current and former interns and is intended to provide practical insights into selected topics from the private equity industry. Speakers are both external and experienced SHS colleagues. For the first session, SHS managed to secure Sebastian Schreiber from SySS as external […]

Read more
1. August 2023 - Newsletter, Portfolio News

Salvia reports successful first application for the treatment of severe migraines in humans

Salvia BioElectronics, a pioneering Dutch company specialising in the treatment and cure of severe migraines, announced the successful first implantation of its paper-thin neuromodulation solution. Migraine is the most common cause of disability in people under 50 and affects one in seven people, mainly women. More than five percent of migraine patients suffer from chronic […]

Read more
1. August 2023 - Newsletter, Portfolio News

PathoQuest announces strategic partnership with Oxford Nanopore Technologies

French company PathoQuest has entered into a strategic partnership with Oxford Nanopore Technologies to bring to market the first sequencing-based quality control test for the genetic characterisation of biopharmaceuticals. Most biologics are produced using genetically modified cell lines. For many cell therapies, the product itself is a genetically modified cell line. Throughout the development of […]

Read more
1
23
...
Next Last